Annual report pursuant to Section 13 and 15(d)

Non-Controlling Interests (Tables)

v3.22.1
Non-Controlling Interests (Tables)
12 Months Ended
Dec. 31, 2021
Non-Controlling Interests  
Schedule of Non-Controlling Interests in Consolidated Entities

Non-controlling interests in consolidated entities are as follows:

    

    

For the Year Ended

    

    

    

    

 

As of December 31, 2021

December 31, 2021

As of December 31, 2021

 

Net loss attributable to

Non-controlling interests

Non-controlling

 

($ in thousands)

    

NCI equity share

non-controlling interests

in consolidated entities

ownership

 

UR-1

$

(442)

$

(1,353)

$

(1,795)

 

34.5

%

Aevitas

(4,159)

 

(901)

 

(5,060)

 

45.9

%

Avenue 2

 

5,739

 

(2,909)

 

2,830

 

82.0

%

Baergic

 

(2,047)

 

(39)

 

(2,086)

 

39.0

%

Cellvation

 

(1,413)

 

(131)

 

(1,544)

 

21.7

%

Checkpoint 1

 

63,464

 

(39,226)

 

24,238

 

81.5

%

Coronado SO

 

(290)

 

 

(290)

 

13.0

%

Cyprium

 

(1,397)

 

(807)

 

(2,204)

 

29.8

%

Helocyte

 

(5,440)

 

(89)

 

(5,529)

 

18.3

%

JMC

 

23,150

 

(5,652)

 

17,498

 

41.6

%

Mustang 2

 

141,527

 

(48,518)

 

93,009

 

82.7

%

Oncogenuity

(627)

 

(497)

 

(1,124)

 

24.9

%

Tamid

 

(739)

 

(1)

 

(740)

 

22.8

%

Total

$

217,326

$

(100,123)

$

117,203

 

  

    

For the Year Ended

    

    

 

As of December 31, 2020

December 31, 2020

As of December 31, 2020

 

Net loss attributable to 

Non-controlling interests 

Non-controlling 

 

($ in thousands)

    

NCI equity share

    

non-controlling interests

    

 in consolidated entities

    

 ownership

 

UR-1

$

(7)

(27)

$

(34)

 

10.0

%

Aevitas

(2,370)

(823)

 

(3,193)

 

39.0

%

Avenue 2

 

5,800

(3,974)

 

1,826

 

77.4

%

Baergic

 

(1,662)

(97)

 

(1,759)

 

39.5

%

Cellvation

 

(1,089)

(182)

 

(1,271)

 

22.1

%

Checkpoint 1

 

41,704

(13,265)

 

28,439

 

80.4

%

Coronado SO

 

(290)

 

(290)

 

13.0

%

Cyprium

 

567

(1,478)

 

(911)

 

30.5

%

Helocyte

 

(4,986)

(259)

 

(5,245)

 

18.8

%

JMC

 

138

491

 

629

 

7.1

%

Mustang 2

 

116,060

(36,429)

 

79,631

 

80.9

%

Oncogenuity

(82)

(376)

 

(458)

 

25.3

%

Tamid

 

(663)

(40)

 

(703)

 

22.8

%

Total

$

153,120

$

(56,459)

$

96,661

 

Note 1:  Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Note 2:  Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.